Amylyx Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AMLX
CUSIP
03237H101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03237H101 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
15.0% 2/5/2026
Event 12/31/2025
Perceptive Advisors LLC 13G/A
7.5% 5/15/2026
Event 3/31/2026
BlackRock, Inc. 13G/A 7.1% 1/21/2026
Event 12/31/2025
TCG Crossover GP II, LLC 13G/A
5.7% 2/17/2026
Event 12/31/2025
Commodore Capital LP 13G
5.1% 11/17/2025
Event 11/10/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Point72 Asset Management, L.P. 13G/A
2.6% 11/14/2025
Event 9/30/2025
Panacea Innovation Ltd 13G/A
2.6% 2/14/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G/A
2.5% 2/12/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 6 12.6 k $367 k
2026 Q2 223 117 M $2.15 B
2026 Q1 184 115 M $1.60 B
2025 Q4 193 112 M $1.36 B
2025 Q3 180 112 M $1.52 B
2025 Q2 136 81.9 M $525 M
2025 Q1 141 73.9 M $262 M
2024 Q4 139 50.0 M $189 M
2024 Q3 120 43.6 M $141 M
2024 Q2 133 44.6 M $84.8 M
2024 Q1 183 54.1 M $154 M
2023 Q4 213 65.1 M $958 M
2023 Q3 195 59.6 M $1.09 B
2023 Q2 174 54.8 M $1.18 B
2023 Q1 170 51.6 M $1.52 B
2022 Q4 155 49.7 M $1.83 B
2022 Q3 123 37.8 M $1.06 B
2022 Q2 96 26.6 M $513 M
2022 Q1 78 23.4 M $300 M